Institution
Children's Hospital Oakland Research Institute
About: Children's Hospital Oakland Research Institute is a based out in . It is known for research contribution in the topics: Population & Human leukocyte antigen. The organization has 1568 authors who have published 2480 publications receiving 203418 citations.
Topics: Population, Human leukocyte antigen, Haplotype, Gene, Cholesterol
Papers published on a yearly basis
Papers
More filters
••
University of Cincinnati1, Children's Hospital Oakland Research Institute2, Children's Mercy Hospital3, Pennsylvania State University4, Children's National Medical Center5, University of California, Irvine6, Boston Children's Hospital7, Washington University in St. Louis8, University of Pennsylvania9, University of Michigan10
TL;DR: The authors have validated the existence of subclasses of children with septic shock based on a biologically relevant, 100-gene expression signature and the subclasses have relevant clinical differences.
Abstract: Objective
Septic shock heterogeneity has important implications for clinical trial implementation and patient management. We previously addressed this heterogeneity by identifying 3 putative subclasses of children with septic shock based exclusively on a 100-gene expression signature. Here we attempted to prospectively validate the existence of these gene expression-based subclasses in a validation cohort.
118 citations
••
TL;DR: It is suggested that alterations in the architecture of the RBC membrane that precede vesiculation lead to selective polarization of GPI-anchored proteins within the domain of the membrane destined to become a vesicle.
118 citations
••
Boston Children's Hospital1, Eli Lilly and Company2, Imperial College London3, Oregon Health & Science University4, Baylor College of Medicine5, Cincinnati Children's Hospital Medical Center6, University of Texas Southwestern Medical Center7, Saint Barnabas Medical Center8, Children's Hospital Oakland Research Institute9, Children's National Medical Center10, Children's Medical Center of Dallas11
TL;DR: A preliminary analysis of the safety, pharmacokinetics, and pharmacodynamic effects, and safety profile of drotrecogin alfa (activated) in pediatric patients with severe sepsis are similar to those previously published for adult patients.
Abstract: Objective. In a phase 3 trial, recombinant human activated protein C (drotrecogin alfa [activated]) significantly reduced mortality in adult patients with severe sepsis. We have now performed a preliminary analysis of the safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in pediatric patients with severe sepsis. Design and Setting. Open-label, nonrandomized, sequential, 2-part study conducted in 11 medical centers in the United States and United Kingdom. Patients. Eighty-three pediatric patients with severe sepsis aged term newborn (≥38 weeks’ gestation) to Intervention. In part 1, drotrecogin alfa (activated) was administered as escalating doses of 6, 12, 24, and 36 μg/kg per hour for 6 hours for each patient (n = 21). In part 2, drotrecogin alfa (activated) was infused at a rate of 24 μg/kg per hour for 96 hours in 62 patients. Main Outcome Measures. Plasma clearance, plasma concentration, D-dimer, protein C, and antithrombin levels were measured, and adverse events were monitored. Results. The trial enrolled 83 pediatric patients with severe sepsis, aged term newborn (≥38 weeks’ gestation) to Conclusions. Pediatric patients with severe sepsis manifest sepsis-induced coagulopathy including protein C deficiency comparable to that seen in adults with severe sepsis. The pharmacokinetics, pharmacodynamic effects, and safety profile of drotrecogin alfa (activated) in pediatric patients are similar to those previously published for adult patients. A large, phase 3, randomized, placebo-controlled study is ongoing to confirm these results and formally assess the safety and efficacy of drotrecogin alfa (activated) in children.
118 citations
••
TL;DR: It is suggested that schizencephaly has heterogeneous etiologies many of which are vascular disruptive in origin, including gastroschisis, bowel atresias, and amniotic band disruption sequence.
Abstract: Schizencephaly is a rare congenital brain defect characterized by gray matter lined clefts of the cerebral mantle, frequently accompanied by other defects of the CNS such as absence of the corpus callosum. This study in a California population of >4 million births from 1985-2001 found a population prevalence of 1.54/100,000. Among 63 cases, there was an association with young parental age in isolated schizencephaly (RR 3.9 mothers; 5.8 fathers), which was also seen in mothers but not fathers of non-isolated cases (RR 3.2). Monozygotic twins may also be at increased risk for schizencephaly (RR 2.1). One third of cases had a non-CNS abnormality, over half of which could be classified as secondary to vascular disruption, including gastroschisis, bowel atresias, and amniotic band disruption sequence. Other apparent rare causes included chromosomal aneuploidy, non-random associations, and unusual syndromes. Our observations suggest that schizencephaly has heterogeneous etiologies many of which are vascular disruptive in origin.
117 citations
••
TL;DR: The extraction procedure and HPLC method facilitated assays of sphingosine kinase with different sphingoid bases as substrates and/or inhibitors and enabled the quantitation of spindingoid base 1-phosphates in human plasma, serum, and platelets as well as in strains of Saccharomyces cerevisae with mutations in sphingolipid metabolism.
117 citations
Authors
Showing all 1568 results
Name | H-index | Papers | Citations |
---|---|---|---|
Frank B. Hu | 250 | 1675 | 253464 |
Bruce M. Psaty | 181 | 1205 | 138244 |
Bruce N. Ames | 158 | 506 | 129010 |
Rino Rappuoli | 132 | 816 | 64660 |
Robert S. Schwartz | 130 | 923 | 62624 |
Carlos López-Otín | 126 | 494 | 83933 |
Ronald M. Krauss | 120 | 438 | 77969 |
Robert S. Stern | 120 | 761 | 62834 |
Joan S. Brugge | 115 | 286 | 47965 |
Ewan Birney | 114 | 308 | 125382 |
Keith M. Sullivan | 105 | 447 | 39067 |
Bo Lönnerdal | 99 | 674 | 36297 |
Dennis E. Discher | 98 | 372 | 60060 |
Richard Reinhardt | 94 | 370 | 58076 |
Henry A. Erlich | 93 | 354 | 40295 |